 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...5354555657585960616263...143144» |
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Aug 18, 2021
P1, N=24, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Sep 2023
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, IO biomarker, Metastases: Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) (clinicaltrials.gov) - Aug 18, 2021
P3, N=495, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Sep 2023 Trial completion date: Jan 2022 --> Aug 2022
- || PF-07284892 / Pfizer
Enrollment change, Combination therapy, Metastases: PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Aug 18, 2021
P1, N=211, Recruiting, Sponsor: Pfizer
Trial completion date: Jan 2022 --> Aug 2022 N=70 --> 211
- || divarasib (RG6330) / Roche
Enrollment change, Combination therapy, Metastases: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (clinicaltrials.gov) - Aug 18, 2021
P1a/1b, N=342, Recruiting, Sponsor: Genentech, Inc.
N=70 --> 211 N=236 --> 342
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Enrollment change, Trial suspension, Surgery: SULTAN: Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network (clinicaltrials.gov) - Aug 18, 2021
P2, N=20, Suspended, Sponsor: UNICANCER
N=236 --> 342 N=140 --> 20 | Recruiting --> Suspended
- | fosifloxuridine nafalbenamide (NUC-3373) / NuCana
Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: NuTide:302: A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment (clinicaltrials.gov) - Aug 18, 2021
P1/2, N=225, Recruiting, Sponsor: NuCana plc
N=140 --> 20 | Recruiting --> Suspended Phase classification: P1 --> P1/2 | N=118 --> 225 | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Systemic therapy for recurrent and/or metastatic head and neck cancer: a population-based healthcare research study in Thuringia, Germany. (Pubmed Central) - Aug 18, 2021
Phase classification: P1 --> P1/2 | N=118 --> 225 | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 This study offers useful information, mainly prior to the availability of immunotherapy, on patient characteristics, treatment patterns, and survival in a German real-world population.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Restoring NK cells functionality via cytokine activation enhances cetuximab-mediated NK-cell ADCC: A promising therapeutic tool for HCC patients. (Pubmed Central) - Aug 18, 2021
A significant improvement in the cytotoxicity against HCC was noticed upon using reactivated NK cells combined with cetuximab. Therefore, this study highlights the potential recruitment of NK immune cells along with cetuximab to enhance cytotoxicity against HCC.
- ||| olomorasib (LY3537982) / Eli Lilly
Enrollment open, Metastases: KEYNOTE E27: Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) (clinicaltrials.gov) - Aug 16, 2021
P1a/1b, N=260, Recruiting, Sponsor: Eli Lilly and Company
Therefore, this study highlights the potential recruitment of NK immune cells along with cetuximab to enhance cytotoxicity against HCC. Not yet recruiting --> Recruiting
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. (Pubmed Central) - Aug 15, 2021
Recently, combination strategies involving MAPK pathway blockade have shown promising results in BRAF V600E-mutated mCRC, and other potential targets continue to be explored. In addition, a greater understanding of the role of BRAF V600E mutation in the pathogenesis of CRC should also continue to fuel advances in the management of patients with mCRC harboring this genetic aberration.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tagrisso (osimertinib) / AstraZeneca
Clinical, Journal: Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression. (Pubmed Central) - Aug 14, 2021
In the large xenograft tumor model, the triple therapy induced the greatest inhibitory effect on tumor growth compared with osimertinib alone and its combination with bevacizumab. Clinical trials of the triple therapy are required for patients with lung cancer with EGFR mutations and HIF-1α/TGF-α.
- ||||| Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Circulating tumor DNA: Interesting study @JAMAOnc➡️ Cetuximab Rechallenge ➕Avelumab in Pretreated #Patients è RAS Wild-type Metastatic #Colorectal #Cancer è baseline ctDNA for #KRAS , NRAS, BRAF, and EGFR-S492R mutation: mOS 11.6 mos & mPFS 3.6 mos. @OncoAlert https://t.co/sJsaswS8WB (Twitter) - Aug 13, 2021
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors. (Pubmed Central) - Aug 13, 2021
These new experiments further support a mechanism in which cetuximab inhibits wild-type (HRAS and NRAS) signals in KRAS G13D colorectal cancers. Video Abstract.
- |||| Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
New P2 trial, Metastases: NAUTICALCRC: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. (clinicaltrials.gov) - Aug 12, 2021
P2, N=103, Not yet recruiting, Sponsor: Pierre Fabre Medicament
- |||| Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical: Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial | Colorectal Cancer | JAMA Oncology | JAMA Network https://t.co/zhghkWR7vu (Twitter) - Aug 12, 2021
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, IO biomarker: AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer. (Pubmed Central) - Aug 12, 2021
The results established herein indicate that targeting AMPK is a potentially promising and effective CRC treatment strategy. Video abstract.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Equipping Natural Killer Cells with Cetuximab through Metabolic Glycoengineering and Bioorthogonal Reaction for Targeted Treatment of KRAS Mutant Colorectal Cancer. (Pubmed Central) - Aug 12, 2021
The resulting NK-92 cells were significantly more effective than the parent NK-92 cells in protecting against tumor development in a KRAS mutant mouse tumor model resistant to cetuximab treatment. Thus, NK cell functionalization with antibodies enabled by metabolic glycoengineering is a promising strategy to enhance anticancer immune therapy.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Review, Journal, IO biomarker: Cetuximab in locally advanced head and neck squamous cell carcinoma: biological mechanisms involved in efficacy, toxicity and resistance. (Pubmed Central) - Aug 12, 2021
Acquired resistance is associated with microenvironment plasticity, which is, in turn, characterized by an increased immune infiltrate. The better definition of patients eligible for this kind of therapy could improve HNSCC management, possibly proposing a combined treatment with radiotherapy, cetuximab and immune checkpoint inhibitors as recently investigated.
- |||| glecirasib (JAB-21822) / Jacobio Pharma
New P1/2 trial, Combination therapy, Monotherapy, Metastases: JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation (clinicaltrials.gov) - Aug 11, 2021
P1/2, N=100, Not yet recruiting, Sponsor: Jacobio Pharmaceuticals Co., Ltd.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Ménétrier-like disease in a Pointer with concurrent granulomatous gastritis, helicobacteriosis and leishmaniosis: a case report. (Pubmed Central) - Aug 11, 2021
The dog here was doing well 39 months after first presentation, which is the longest reported survival time for Ménétrier-like disease with only palliative treatment in dogs. Full-thickness biopsies are preferred in macroscopic hypertrophic lesions of the stomach for better assessment of Ménétrier-like disease.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Stivarga (regorafenib) / Bayer
New trial: Organoids-on-a-chip for Colorectal Cancer and in Vitro Screening of Chemotherapeutic Drugs (clinicaltrials.gov) - Aug 8, 2021
P, N=52, Recruiting, Sponsor: Peking University People's Hospital
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Current perspectives on the treatment of BRAF mutated colorectal carcinoma. (Pubmed Central) - Aug 8, 2021
Furthermore, this combination has shown well-tolerated safety profile with manageable toxicities. The aim of this article is a review of current treatment options for BRAF mutated colorectal cancer.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Choosing the Right Treatment Option for the Right R/M HNSCC Patient: Should We Adhere to PFE for First-Line Therapy? (Pubmed Central) - Aug 7, 2021
Subgroup analyses highlight the lasting value of PFE among the growing spectrum of 1L-ChT. Importantly, fit smokers with high level alcohol consumption benefit from PFE; considering the patient's lifestyle factors, PFE should not be ignored in decision-making.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: In reply to the Letter to the Editor by Chen and Lui regarding "Radiotherapy enhances uptake and efficacy of Y-cetuximab: A preclinical trial" by A Dietrich et al. (Pubmed Central) - Aug 7, 2021
Importantly, fit smokers with high level alcohol consumption benefit from PFE; considering the patient's lifestyle factors, PFE should not be ignored in decision-making. No abstract available
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Letter to the editor of radiotherapy and oncology regarding of the paper "Radiotherapy enhances uptake and efficacy of Y-cetuximab: A preclinical trial" by A Dietrich et al. (Pubmed Central) - Aug 7, 2021
No abstract available No abstract available
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Retrospective data, Journal: Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era. (Pubmed Central) - Aug 7, 2021
The weekly schedule appears to be an active and safe strategy in frail patients with R/M HNSCC. Based on these data, a weekly schedule could be considered as a first line treatment in all frail patients excluded from pembrolizumab treatment and a study on the combination of weekly chemotherapy and immunotherapy should be performed.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, HEOR: Quality of Life in Patients With Severe Skin Reactions in Course of First-Generation Epidermal Growth Factor Receptor Inhibitors Monoclonal Antibodies (Our Experience With Cetuximab). (Pubmed Central) - Aug 6, 2021
Data showed a significant impact in psychological sphere and social relationships. Skin side effects, particularly rash, influence QoL and social relationships, compromising therapeutic compliance.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, Real-world evidence: Outcome of patients with recurrent/metastatic squamous cell head and neck cancer treated with platinum-based chemotherapy with or without cetuximab in real-world practice. (Pubmed Central) - Aug 6, 2021
The proportion of patients who died under treatment due to disease progression and toxicity was high in both treatment arms. A thorough selection of patients for this treatment is crucial.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Review, Journal: Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies. (Pubmed Central) - Aug 6, 2021
The addition of RTKis to radiotherapy-based treatment did not improve overall survival (hazard ratio = 1.02, 95% confidence interval = 0.90 to 1.15, P = .76) but increased grade 3+ toxicity (relative risk = 1.18, 95% confidence interval = 1.06 to 1.33, P = .009). The addition of RTKis to radiotherapy does not improve survival and worsens toxicity.
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P2 data, Journal, Adverse events: Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. (Pubmed Central) - Aug 6, 2021
For patients who were reported as asymptomatic by the physician, the presence of patient-reported symptoms resulted in a trend toward poor prognostic outcomes for appetite loss, dyspnea, diarrhea, and constipation. These findings provide the clinical importance of the monitoring of patient-reported symptoms that can be complementary to physician-reported data to ensure more accurate clinical outcomes.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Predicting the efficacy of chemoradiotherapy for locally advanced human papilloma virus-related oropharyngeal squamous cell carcinoma using one course of TPF chemotherapy. (Pubmed Central) - Aug 6, 2021
These findings provide the clinical importance of the monitoring of patient-reported symptoms that can be complementary to physician-reported data to ensure more accurate clinical outcomes. When facing difficulty in deciding between chemoradiotherapy and surgery, one course of TPF may be an effective option.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Observational data, Journal, PD(L)-1 Biomarker, IO biomarker: Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC). (Pubmed Central) - Aug 4, 2021
P=N/A
Potential future targets to be combined with RT in the conventional treatment and anti-PD1/PD-L could be BTLA agonists, or agonistic antibodies to co-stimulatory ICM like CD137, OX40 or GITR. The combination of cetuximab with CD27 agonistic antibodies enhancing ADCC or the targeting of TIM3 / LAG3 may be another promising strategy.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Tumor Mutational Burden: Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer. (Pubmed Central) - Aug 4, 2021
Anti-EGFR antibodies such as cetuximab are active against KRAS/NRAS wild-type colorectal cancers (CRCs), but acquired resistance invariably evolves...This result suggests that chemotherapy mutagenesis can accelerate resistance evolution. Mutational signatures may be a new class of cancer evolution predictor.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer. (Pubmed Central) - Aug 4, 2021
Carfilzomib displayed potent antiproliferative effects, induced the unfolded protein response as determined by enhanced CHOP expression and ATF6 activity, and enhanced apoptosis as determined by enhanced caspase-3/7 activity. Overall, our results indicate a potentially novel indication for carfilzomib: that of a potential alternative agent to treat cetuximab-resistant colorectal cancer.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Hocena (antroquinonol) / Golden Biotechnology
Biomarker, Journal: 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis. (Pubmed Central) - Aug 4, 2021
In summary, our findings provide strong evidence regarding the therapeutic effect of 4-AAQB on KRAS-mutant CRC cells. Furthermore, 4-AAQB effectively inhibits Ras singling in CRC cells, through which KRAS-mutant CRC can be resensitized to cetuximab.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P2 data, Journal: Continuing Cetuximab vs Bevacizumab plus chemotherapy after first progression in wild-type KRAS, NRAS and BRAF V600E metastatic colorectal cancer: a randomized phase II trial. (Pubmed Central) - Aug 3, 2021
The results showed no significant difference in PFS, OS and ORR between the two arms, but a trend in favor of the cetuximab continuation plus chemotherapy crossover was examined in all end points. High expression of MET in cetuximab-progressed tumors may indicate an existence of MET-dependent tumor cell population.
- Hensify (crystalline hafnium oxide) / Nanobiotix, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] A phase I study of radiation enhancing functionalized hafnium oxide nanoparticles in cisplatin-ineligible patients with locally advanced HNSCC () - Aug 3, 2021 - Abstract #AHNS2021AHNS_863;
NBTXR3 intratumoral administration followed by IMRT is well tolerated and safe in elderly patients or patients with multiple comorbidities with LA-HNSCC. NBTXR3 activated by RT showed promising anti-tumor efficacy, which warranties further evaluation in a phase III randomized trial, and it may represent a valuable treatment option for patients with LA-HNSCC.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Presurgical Chemotherapy for HPV Positive Oropharyngeal Squamous Cancers () - Aug 3, 2021 - Abstract #AHNS2021AHNS_802;
However, given HPV related tumors of the oropharynx have a more favorable prognosis regardless of treatment, radiotherapy was avoided in most patients without sacrificing survival. With the advent of newer chemotherapies and surgical techniques, radiation now has the highest treatment morbidity.
- Akalux (cetuximab sarotalocan) / Rakuten Medical, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC): Efficacy and safety results from a subgroup analysis in anti-PD1 treated and anti-PD1 naïve patients () - Aug 3, 2021 - Abstract #AHNS2021AHNS_651;
Preliminary data from this subgroup analysis suggest promising clinical activity with response rates of >40% observed in patients with or without prior anti-PD1. In both groups, treatment with RM-1929 photoimmunotherapy did not result in any unexpected safety findings.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Analysis of the synergetic effect of autophagy inhibitor chloroquine in combination with cetuximab or cisplatin in head and neck squamous cell carcinoma cell lines () - Aug 3, 2021 - Abstract #AHNS2021AHNS_308;
In both groups, treatment with RM-1929 photoimmunotherapy did not result in any unexpected safety findings. These results suggest that autophagy is an important target in HNSCC and that the combination of autophagy inhibition with CQ to standard of care chemotherapy represents a promising therapeutic strategy in HNSCC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Surgical resection for huge recurrent right colon carcinoma after cetuximab plus FOLFIRI. (Pubmed Central) - Aug 1, 2021
These results suggest that autophagy is an important target in HNSCC and that the combination of autophagy inhibition with CQ to standard of care chemotherapy represents a promising therapeutic strategy in HNSCC. No abstract available
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical: Phase 3 BREAKWATER trial #BRAF V600e #colorectal cancer Encorafenib + Cetuximab w/ or w/o chemotherapy 1st line setting Dr. @skopetz of @MDAndersonNews "...the study is critical because this is a patient population w/ substantial unmet treatment needs." https://t.co/lQahmIx66R (Twitter) - Aug 1, 2021
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Colorectal Cancer: From Genetic Landscape to Targeted Therapy. (Pubmed Central) - Jul 31, 2021
Targeted therapy has led to great improvement in the treatment of metastatic CRC. However, there has been variability in CRC treatment outcomes due to molecular heterogeneity in colorectal tumors, which underscores the need for identifying prognostic and predictive biomarkers for CRC-targeted drugs.
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Next-generation sequencing: FIRE-3 patients who underwent sec. resection had longer OS when being treated with cetuximab - one third developed molecular resistance. See the latest results of matched specimen NGS data before and after sec. resection: https://t.co/4tClUwUrX7 @StintzingS @BenWestphalen (Twitter) - Jul 31, 2021
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tecentriq (atezolizumab) / Roche
[VIRTUAL] RT+cisplatin vs. RT+docetaxel+cetuximab vs. RT+cisplatin+atezolizumab for “high risk” resected HNSCC (Phase IIIR) () - Jul 30, 2021 - Abstract #NRGVIRTUAL2021NRG_VIRTUAL_35;
- || RX208 / Suzhou NeuPharma, Fosun Pharma
New P2 trial, Metastases: The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment (clinicaltrials.gov) - Jul 30, 2021
P2, N=50, Not yet recruiting, Sponsor: Shanghai Henlius Biotech
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX). (Pubmed Central) - Jul 30, 2021
This prospective study included patients with mCRC treated with first-line chemotherapy plus cetuximab...Expression of Th2-related and keratinocyte-derived cytokines in the skin was associated with anti-EGFR efficacy. If this inflammatory signature can explain the rash, the exact mechanism by which these cytokines are involved in anti-EGFR tumor response remains to be studied.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: ErbB1-dependent signalling and vesicular trafficking in primary afferent nociceptors associated with hypersensitivity in neuropathic pain. (Pubmed Central) - Jul 29, 2021
Overall these findings newly reveal both upstream and downstream signals to explain how ErbB1 can act as a signalling hub in neuropathic pain models and identify the trafficking of key ion channels to neuronal subcellular locations likely to contribute to hyperexcitability. The new concept of combined treatment with ErbB1 plus ErbB2 blockers is mechanistically validated as a promising strategy for the relief of neuropathic pain.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: EFFECTIVENESS OF FIRST-LINE CETUXIMAB IN WILD-TYPE RAS METASTATIC COLORECTAL CANCER ACCORDING TO TUMOUR BRAF MUTATION STATUS FROM THE EREBUS COHORT. (Pubmed Central) - Jul 28, 2021
The new concept of combined treatment with ErbB1 plus ErbB2 blockers is mechanistically validated as a promising strategy for the relief of neuropathic pain. BRAF mutations were associated with markedly poorer outcomes in initially unresectable RASwt mCRC patients treated by cetuximab in first-line treatment.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, Real-world evidence: A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer. (Pubmed Central) - Jul 28, 2021
Median OS was 12.8 months in the RT + Cet group versus 7.9 months in the CT + Cet group (hazard ratio for death, 0.50, 95% CI, 0.33-0.75, p = 0.0008). In conclusion, radiotherapy combined with cetuximab improved survival compared to chemotherapy combined with cetuximab in locally recurrent HNSCC.